Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is IM Cannabis Corp. (IMCC) Stock Down -16.67% Today?

Why Is IM Cannabis Corp. (IMCC) Stock Down -16.67% Today?

Key Takeaways

  • IMCC dropped 16.67% to $0.45 in midday trading, sliding from a prior close of $0.54 and back toward the all-time low of $0.45 set on November 16.
  • The primary catalyst is corporate: the board approved a 3-for-1 share consolidation effective November 23 to chase Nasdaq's $1.00 minimum bid price — while warning that a second reverse split inside 12 months forfeits the standard 180-day cure period, leaving a Staff Delisting Determination possible after 30 consecutive sub-$1 closes.
  • Secondary pressure came from a collapsed revenue base: third-quarter continuing-operations revenue of C$1.65 million versus C$5.08 million a year earlier, a gross loss, and a widened net loss of C$7.08 million.
  • Discount-to-VWAP convertible notes and a large registered resale block keep feeding new, immediately sellable supply into a float of roughly 1.8 million shares.
  • The move was company-specific rather than sector-driven, with thin turnover and a market value near $0.8 million amplifying the percentage swing.
  • News Significance Score: 40/100 — Material listing-compliance news, but a decline only about 1.8 times the stock's typical daily move.
  • What traders are watching next: the November 23 post-split open, whether the bid holds above $1.00, progress on the Space Defense Innovations purchase, and the fourth-quarter report.
  • For deeper research on IMCC, explore dedicated pages covering Price Targets, Earnings, and Forecast data.
  • Investors tracking fast-moving, sentiment-driven setups can also review the curated Trending AI Robots list of top-performing trading bots.

Opening Summary

IM Cannabis Corp. (NASDAQ: IMCC) is a micro-cap medical cannabis company headquartered in Israel that imports and distributes cannabis to patients and operates retail pharmacies and online platforms. Shares were trading at $0.45 at midday, down 16.67% from the previous session's close of $0.54, confirming a decisively negative move. The immediate reason cited by the market is the company's announcement that it will execute a 3-for-1 share consolidation on November 23 to support compliance with Nasdaq's $1.00 minimum bid price requirement, together with its disclosure that it is no longer eligible for a standard compliance period because it already completed a 30-for-1 consolidation on August 27, 2026.

Reverse Split Cuts Both Ways

The consolidation reduces issued shares from roughly 1,844,162 to about 614,721 at a 1-for-3 ratio. Mechanically, that lifts the quoted price — a $0.54 close becomes roughly $1.61 on paper. Investors, however, focused on the second half of the release: because IMCC effected a reverse split within the prior year, Nasdaq Listing Rule 5810(c)(3)(A)(iv) denies it the usual 180-calendar-day cure period. If the closing bid stays below $1.00 for 30 consecutive business days, Nasdaq staff would issue a Staff Delisting Determination. For a company that has now consolidated its shares four times in five years, the announcement reads less like a fix than a countdown, and the stock was sold accordingly.

Revenue Collapse Undercuts the Story

The reverse split landed five days after third-quarter results that gave shareholders little to anchor on. Continuing-operations revenue fell to C$1.65 million from C$5.08 million, a gross loss of C$35,000 replaced a year-earlier gross profit of C$1.58 million, and the net loss widened to C$7.08 million from C$3.87 million. Nine-month losses reached C$13.93 million. Cash stood at C$2.4 million against total liabilities of C$16.7 million and a shareholders' deficit of C$2.99 million. With European operations sold off in late September, the remaining Israeli platform is small, loss-making, and reliant on external financing.

Dilution Overhang and Financing Terms

On November 4 the company closed a US$1.2 million convertible note with a 15% original issue discount, conversion at the lower of $0.610 or 85% of the lowest daily VWAP over the prior 20 sessions, and warrants on nearly 3.94 million shares — a sum more than double the current share count. Because conversion prices reset lower as the stock weakens, each tranche adds supply into a falling market. A large registered resale block filed in November reinforced the perception of persistent selling pressure.

Market Context and Trading Activity

Turnover was thin even by this stock's modest standards, with recent sessions averaging roughly 40,000 shares; a float that small turns modest sell orders into outsized percentage moves. The decline was issuer-specific and did not reflect a broad cannabis-sector move. Technically, the stock sits at the bottom of a violent downtrend: it closed at $4.23 on September 18 after a drone-acquisition rally briefly pushed it as high as $8.65 on enormous volume, and has lost more than 89% since. It is trading below every meaningful moving average and at the low end of a 52-week range of $0.45 to $62.40, with the November 16 all-time low now acting as the only visible reference point.

News Significance Score

On a scale where 0 means no meaningful news and a normal price move, and 100 means transformative news and an extreme, rare move, IMCC scores 40 out of 100. The verified news was genuinely material for a company of this size: a reverse split tied to listing compliance, an explicit delisting warning, and a sharply smaller revenue base. The price behavior, however, was not extreme by the stock's own standards. The decline was roughly 1.8 times the typical daily move of about 9.3%, and sessions with equal or larger absolute moves occurred eight times in the last 60 trading days. Strong news paired with a routine-for-this-stock swing produces a mid-range score.

What Comes Next for IMCC

The November 23 effective date is the immediate checkpoint: post-consolidation trading begins at the open, and the market will quickly show whether the bid can hold above $1.00. A sustained sub-$1 print restarts the 30-business-day delisting clock. Also pending is the non-binding letter of intent to acquire 51% of Poland's Space Defense Innovations, a tactical drone reseller; no definitive agreement has been signed, and no assurance of completion exists. Fourth-quarter results, expected in the new year, will show whether the slimmed-down Israeli operation can stabilize revenue. Analysts provide minimal coverage, and the key risks are straightforward: further equity issuance, conversion-driven dilution, and exchange compliance.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and traded symbols, so the page offers a practical way to compare approaches side by side. For readers tracking volatile names like this one, reviewing the current leaders is a useful next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMCC

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


IMCC's RSI Indicator ascending out of oversold territory

The RSI Oscillator for IMCC moved out of oversold territory on November 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 38 of the 41 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 66 cases where IMCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 162 of 192 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

IMCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for IMCC entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.070) is normal, around the industry mean (6.379). P/E Ratio (-0.006) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
Central District
Phone
+972 773603504
Employees
44
Web
https://www.imcannabis.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.